Glutamate levels may be informative about the declining neuronal health in the central nervous system. We used an advanced proton MR spectroscopy ( 1 H-MRS) protocol composed of semi-localization by adiabatic selective refocusing (sLASER) localization and FAST(EST)MAP shimming for detection of alterations in brain glutamate concentrations in patients with amnestic mild cognitive impairment.
Introduction
Biomarkers of Alzheimer disease (AD)-associated neurodegeneration are critical for early diagnosis, for tracking early disease progression, and identifying individuals for potential preventive interventions. Furthermore, such biomarkers may provide a window into the mechanisms of neurodegeneration in AD.
Glutamate homeostasis is accomplished by the neuronastrocyte interaction and glutamate concentration is altered by neuronal density and neurodegeneration.
1,2 Therefore, a decrease in glutamate levels in the central nervous system would be a potential biomarker of declining neuronal health. We hypothesized that decreased glutamate levels can be observed in the posterior cingulate gyrus of patients with amnestic mild cognitive impairment (aMCI) compared to controls as an early biomarker of neurodegeneration.
Proton magnetic resonance spectroscopy ( 1 H-MRS) detects neurochemicals that are associated with neuronal or synaptic integrity, glial activation, and the pathologic stage of AD. [3] [4] [5] These neurochemical alterations are detected as early as the prodromal stage of AD, such as in patients with aMCI. 6 For example, elevation of myo-inositol can be detected in patients with aMCI, before the decrease in the neuronal integrity biomarker N-acetyl-aspartate (NAA) in patients with AD. 7 In contrast to metabolites that are consistently abnormal in AD such as NAA and myo-inositol, 8 little is known about glutamate, a metabolite excluded in most of the aMCI studies because of the methodological difficulties in separating glutamate from the glutamine signal using conventional acquisition protocols. However, reliable separation of glutamate and glutamine in 1 H-MRS strongly depends on both the spectral data quality and the data analysis methods.
The conventional full intensity 1 H-MRS protocols are hampered by large chemical shift displacement errors (CSDEs) at 3T. 9 In contrast, the semi-localization by adiabatic selective refocusing (sLASER) methodology achieves more accurate localization with minimal CSDE. 10, 11 Importantly, an optimized sLASER protocol that incorporates variable pulse power optimized relaxation (VAPOR) water suppression, outer volume suppression, voxel-based B 0 and B 1 calibrations, and FAST(EST)MAP shimming enables highly reproducible metabolite quantification at 3T, with betweensession coefficients of variance (CV) ࣘ 5% for the five major neurochemicals, including glutamate.
12 sLASER protocol's advanced features improve the spectral quality through superior water suppression, minimization of unwanted coherences, and negligible CSDE at short echo-times. The FAST(EST)MAP shimming, 13 utilized for localized shimming together with the sLASER protocol, further contributes to the improvement in the metabolite quantification, by providing narrower spectral linewidths.
The conventional 1 H-MRS protocols were commonly used in previous studies in patients with aMCI. 7, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, findings regarding glutamate alterations in patients with aMCI have been inconsistent using conventional 1 H-MRS acquisitions, and glutamate has been reported as a sum with the metabolite glutamine (Glx). [24] [25] [26] [27] An advanced sLASER protocol may provide reliable quantification of glutamate and identify early glutamate alterations in patients with aMCI.
In this study, an advanced sLASER 1 H-MRS protocol was used in the clinical setting to test the feasibility of detecting glutamate and to determine whether glutamate levels measured by the advanced sLASER protocol are decreased in patients with aMCI.
Methods Participants
Consecutive participants with aMCI using the most recent diagnostic criteria 6 (n = 14) and age-and sex-frequency matched clinically normal controls (CN; n = 32) from the populationbased Mayo Clinic Study of Aging 28 were prospectively recruited to this study.
In addition to clinical evaluations and neuropsychological testing, to make sure we captured the lowest risk for the AD group, controls had to have low β-amyloid load on [
11 C] Pittsburgh Compound B (PiB)-PET (standard uptake value ratio; SUVr < 1.42). To capture the highest risk for the AD group, patients with aMCI had to have high β-amyloid load (SUVr ࣙ 1.42) 29 on their most recent PiB-PET scan that was performed on average within 15 months of the 1 H-MRS examination. Individuals who had a neurological disorder such as a brain tumor, epilepsy, multiple sclerosis, or stroke that would have an effect on 1 H-MRS measurements were not invited to participate in this study.
Participants were enrolled after giving informed consent and the approvals were obtained from the Institutional Review Board.
MRI and 1 H-MRS Acquisitions
All participants underwent the 1 H-MRS acquisition scheme in one scanning session: the advanced modified sLASER protocol with FAST(EST)MAP B 0 shimming. 10 The study was conducted by three rotating clinical MRI technologists on a 3T Verio scanner (Siemens Medical Solutions, Erlangen, Germany), operating with the VB17 software. A 32-channel phased array head coil was used for signal reception.
The 1 H-MRS voxel included the posterior cingulate gyri bilaterally (Fig 1) . In order to select an 8 mL of volume-of-interest in the posterior cingulate gyrus, a 3D T 1 -weighted MPRAGE sequence (T R /T E = 2,300/2.98 ms, spatial resolution = 1 × 1 × 1.2 mm 3 ) was performed. The posterior cingulate cortex is an important hub for resting-state connectivity networks, 30 it is affected by AD's β-amyloid pathology, 31 and shows high PiB uptake. 32 The posterior cingulate cortex is also affected by neurofibrillary tangle tau pathology of AD, relatively earlier than other neocortical regions in the disease course. 33 Furthermore, the posterior cingulate cortex is a region of reduced glucose metabolism in cognitively normal individuals with a genetic risk of AD. 34 A single-voxel proton spectrum for each individual was acquired in the same session using sLASER 10 sequence with VA-POR water suppression (T R /T E = 5,000/28 ms, 64 averages) and FAST(EST)MAP shim. 13 In addition, unsuppressed water signals were acquired for eddy current correction and for absolute quantification, as described previously. 35 
Metabolite Quantification
Participants were scanned at the Mayo Clinic. The raw de-identified 1 H-MRS data were transferred to the University of Minnesota for postprocessing using Matlab (MathWorks, Inc., Natick, MA, USA). Eddy current corrected spectra were quantified with LCModel 6.3-0G 36 using water scaling. Previously published chemical shifts and J-coupling values were utilized to simulate basis sets with density-matrix formalism. 37, 38 Nonlocalized simulation with actual radiofrequency shapes and timings was used, due to the low CSDE. To determine the cerebrospinal fluid (CSF) contribution in the volume-of-interest, 12 T E s (28-4,000 ms) were utilized to acquire fully relaxed unsuppressed water signals with the sLASER sequence 35, 39 and concentrations of all metabolites were quantified after correcting for the CSF content in the voxel.
Metabolites that had Cramér-Rao lower bounds (CRLBs) ࣘ20% in at least 50% of the acquired spectra were selected for analysis. 40 If the correlation coefficient between two metabolites was <-.7, then the sum of the metabolites was used; such that total creatine (Cr) included creatine and phospho-creatine, total choline (Cho) included glycerophosphocholine and phosphocholine, and total NAA included N-acetyl-aspartate and N-acetyl-aspartylglutamate. Because myo-inositol elevation is expected in patients with aMCI, we also investigated glutamate/myo-inositol ratio.
PiB-PET
A PET/CT scanner (DRX; GE Healthcare, Waukesha, WI, USA) operating in 3-dimensional mode was used for PiB-PET imaging. After the subjects were injected with PiB (292-729 MBq) and following a 40-minute uptake period, a 20-minute PiB scan was obtained. Four 5-minute dynamic frames at 40-60 minutes postinjection were acquired. As previously described, PET analysis was performed using an automated image processing pipeline. 41 The bilateral parietal, temporal, prefrontal, orbitofrontal, and anterior cingulate gray matter regions referenced to cerebellar gray matter were used to obtain the global cortical PiB retention SUVr. 41 A global cortical-to-cerebellar ratio cutoff point of ࣙ1.42 was obtained to classify participants as having high β-amyloid load. 29 This specific cutoff point was defined by the reliable worsening cut-point method, which distinguishes individuals as having high or low β-amyloid load. 29 
Statistical Analysis
Group differences were assessed using Fisher's Exact or Wilcoxon Rank Sum tests. We used Spearman correlations to measure associations between PiB-PET SUVrs and metabolite concentrations or ratios quantified by sLASER in the entire cohort and in the CN and the aMCI groups separately. Area under receiver operating characteristic curve (AUROC) analysis was carried out to measure the ability of the sLASER protocol to distinguish the two clinical groups using 1 H-MRS metabolite concentrations and ratios.
Results
A total of 46 individuals who were either CN (n = 32) or aMCI (n = 14) were recruited to the study (Table 1) . Age, sex, or time between PiB-PET and MRI/ 1 H-MRS did not differ between groups. As expected, the Mini-Mental State Examination scores were lower (P < .001) and PiB-PET SUVrs and the frequency of APOE ε4 carriers were higher in the aMCI group than the CN group (P < .01).
Glutamate concentration and the glutamate/myo-inositol ratio were lower in the aMCI group than the CN group using the sLASER protocol (P < .05). No differences were found for creatine, myo-inositol, choline, and NAA concentrations between patients with aMCI and CNs (P > .05) ( Table 2 ). The boxplots in Figure 2 show the distribution of individual participants' values. The AUROC estimates were used to distinguish patients with aMCI and CNs for each metabolite concentration and ratio. Glutamate concentration could separate aMCI and CN groups with an AUROC estimate of .70 (95% confidence interval: .51-.85) and the glutamate/myo-inositol ratio with an AUROC estimate of .71 (95% confidence interval: .54-.86) (Fig 3) .
There was a negative correlation between the global cortical PiB-PET SUVr and glutamate/myo-inositol ratio in the entire cohort of 46 participants (r = -.3, P = .04). However, there were no significant correlations between PiB-PET SUVr and metabolite levels or ratios when CNs and patients with aMCI were investigated separately. Figure 4 displays the example of 1 H-MR spectra and PiB-PET of a CN individual and a patient with aMCI. 
Discussion
In this study, we observed that glutamate concentration and glutamate/myo-inositol ratio were lower in patients with aMCI, compared to the CN individuals. Furthermore, glutamate/myoinositol ratios measured by sLASER inversely correlated with global cortical PiB-PET SUVr.
Patients with aMCI who have high β-amyloid deposition on PiB-PET are at an increased risk of progressing to AD dementia than patients with aMCI, who do not have elevated levels of β-amyloid. 6, 42, 43 We studied the patients with aMCI with high β-amyloid load to investigate the accuracy of advanced sLASER protocol in distinguishing patients with aMCI from CN individuals who had low β-amyloid deposition on PiB-PET. In addition to glutamate levels, we also evaluated the glutamate/myo-inositol ratio in order to increase the diagnostic sensitivity, because myo-inositol levels tend to be higher in the aMCI group compared to the CN group. We were unable to study glutamine levels separately, since glutamine did not have CRLBs ࣘ 20% in at least 50% of the acquired spectra.
Glutamate is the primary excitatory neurotransmitter of the central nervous system. After being released from the neuron into the synapse, it is removed by the astrocytes, where it is transformed into glutamine and sent back to the neuron to be reused as glutamate. As such, glutamate is a marker for the health of neuron-astrocyte interaction and contributes to mechanisms of neuronal function, plasticity, metabolism, as well as excitotoxicity.
1,2 Excessive and prolonged excitatory glutamatergic stimulation leads to neuronal cell death, 44, 45 which is a feature of neurodegeneration observed in AD. Neurodegeneration leads to a reduction in glutamate levels due to loss of neuronal viability and synaptic activity.
1 H-MRS typically detects the combined peaks of glutamate plus glutamine (Glx), since it is difficult to separate them by conventional protocols. Hence, the previously reported results of reduced Glx in patients with aMCI and AD may be due to glutamate or glutamine or both. The advanced sLASER protocol enabled the detection of a glutamate reduction in patients with aMCI, which was not demonstrated with conventional PRESS protocols in patients with aMCI. [24] [25] [26] [27] 46 Previous studies using conventional protocols have reported reduced concentrations of Glx in patients with aMCI 24 and AD dementia [46] [47] [48] or normal Glx levels in patients with aMCI. [25] [26] [27] 46 Using sLASER acquisition from the hippocampus, decreased glutamate concentration was demonstrated in patients with AD dementia, but not in patients with aMCI. 49 In the current study, we were able to detect decreased glutamate levels in the aMCI group compared to the CN group in the posterior cingulate gyrus, using the advanced sLASER protocol. This was particularly noteworthy considering the small sample size. The reasons for the discrepant findings may be twofold: (1) the hippocampus, being close to the tissue-air-bone-CSF interface at the skull base, is a difficult region for shimming. In contrast, the posterior cingulate gyrus is not close to the skull base, which may improve the detection of metabolite alterations; (2) there may be regional differences in glutamate reduction in AD, affecting the posterior cingulate cortex more significantly than the hippocampus. For example β-amyloid deposition on PiB-PET is significantly higher in the posterior cingulate cortex, compared to the medial temporal lobe in AD. 41 In fact, we observed a correlation between global cortical PiB-PET SUVr and the glutamate/myoinositol ratio. This correlation may also be driven by the patients with aMCI who had higher PiB-PET SUVr values as one of the study inclusion criteria and had lower glutamate/myo-inositol ratios.
Earlier 1 H-MRS studies in patients with aMCI, conducted using the conventional protocols, such as PRESS, showed that the 1 H-MRS abnormalities identified in patients with aMCI were similar, but only milder compared to the abnormalities identified in patients with AD dementia. 8, 14, 16, 18, 21, 25, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] In patients with aMCI, the elevation in the myo-inositol level was shown to precede the decrease in the NAA level. 7, 21, 62 Longitudinal alterations in 1 H-MRS metabolites and the relationship between metabolite concentrations and cognition in patients with aMCI and AD dementia were also demonstrated. 15, 17, 19, 20, 22, 23, 26, 27, 46, [62] [63] [64] [65] [66] [67] [68] [69] [70] Although the myo-inositol concentration was relatively higher in the aMCI group than the CN group in the current study, the differences between groups were not statistically significant. This is likely due to the smaller sample size, a limitation of the current study, relative to prior studies that reported myoinositol elevation in patients with aMCI. 15, 19, 22, 26, 27, 71 We also did not find a difference in total NAA levels between groups, which is in agreement with previous findings that an alteration in the total NAA level is not typically observed until patients with aMCI progress to AD dementia. 20 It is possible that if brain regions other than the posterior cingulate gyrus are studied, our findings may change. For example, reduced glutamate levels were not observed in the hippocampus of patients with aMCI compared to controls. 49 Glutamate neurotransmission and glutamate-glutamine cycling alterations play an important role in AD-related neuronal damage. 72 The advanced sLASER protocol can be implemented in the clinical setting, and through reliable quantification of glutamate, may contribute to the understanding of pathophysiologic mechanisms of early neurodegeneration in AD. Although our findings are from the posterior cingulate cortex, depending on the stage of the neurodegeneration associated with AD pathophysiology, findings may change over time in other regions of the brain. Future research on the longitudinal outcomes of patients with aMCI with glutamate reduction and monitoring the longitudinal change in glutamate levels may contribute to the understanding of early disease mechanisms in patients with aMCI.
